{"id":42342,"date":"2018-09-14T18:18:19","date_gmt":"2018-09-14T16:18:19","guid":{"rendered":"https:\/\/newserver.fyb.de\/gleiss-lutz-advises-boehringer-ingelheim-on-acquisition-of-viratherapeutics\/"},"modified":"2018-09-14T18:18:19","modified_gmt":"2018-09-14T16:18:19","slug":"gleiss-lutz-advises-boehringer-ingelheim-on-acquisition-of-viratherapeutics","status":"publish","type":"post","link":"https:\/\/www.fyb.de\/en\/gleiss-lutz-advises-boehringer-ingelheim-on-acquisition-of-viratherapeutics\/","title":{"rendered":"Gleiss Lutz advises Boehringer Ingelheim on acquisition of Viratherapeutics"},"content":{"rendered":"<p><span class=\"s1\">Ingel\u00adheim am Rhein<\/span>, Germany \u2014 German phar\u00admaceu\u00adti\u00adcal group <strong>Boeh\u00adrin\u00adger Ingel\u00adheim<\/strong> has acqui\u00adred all shares in Austria-based <strong>Vira\u00adThe\u00adra\u00adpeu\u00adtics<\/strong> GmbH, a biophar\u00admaceu\u00adti\u00adcal company rese\u00adar\u00adching inno\u00adva\u00adtive virus-based immu\u00adno\u00adthe\u00adra\u00adpeu\u00adtics for the treat\u00adment of cancer. Through this biotech acqui\u00adsi\u00adtion with a <strong>tran\u00adsac\u00adtion volume of 210 million euros<\/strong>, Boeh\u00adrin\u00adger Ingel\u00adheim is further expan\u00adding its commit\u00adment in this area. Boeh\u00adrin\u00adger Ingel\u00adheim was advi\u00adsed on this tran\u00adsac\u00adtion by Gleiss<strong>Lutz<\/strong>.<\/p>\n<p>Back in 2016, Boeh\u00adrin\u00adger Ingel\u00adheim ente\u00adred into a colla\u00adbo\u00adra\u00adtion with Vira\u00adThe\u00adra\u00adpeu\u00adtics: Their goal was to deve\u00adlop onco\u00adly\u00adtic viru\u00adses, which are among the most promi\u00adsing new thera\u00adpeu\u00adtic approa\u00adches in cancer rese\u00adarch. In this context, the Boeh\u00adrin\u00adger Ingel\u00adheim Venture Fund (BIVF) was alre\u00adady one of the core inves\u00adtors in the Austrian company. A purchase option had also been agreed as part of the coope\u00adra\u00adtion. Boeh\u00adrin\u00adger Ingel\u00adheim has now exer\u00adcised this. Gleiss Lutz had alre\u00adady compre\u00adhen\u00adsi\u00advely advi\u00adsed Boeh\u00adrin\u00adger Ingel\u00adheim on the conclu\u00adsion of the coope\u00adra\u00adtion in&nbsp;2016.<\/p>\n<p>Boeh\u00adrin\u00adger Ingel\u00adheim is one of the worl\u00add\u2019s top 20 phar\u00admaceu\u00adti\u00adcal compa\u00adnies. Head\u00adquar\u00adte\u00adred in Ingel\u00adheim, Germany, Boeh\u00adrin\u00adger Ingel\u00adheim has 145 affi\u00adlia\u00adted compa\u00adnies world\u00adwide and employs a total of appro\u00adxi\u00adm\u00adately 50,000 people. In 2017, Boeh\u00adrin\u00adger Ingel\u00adheim gene\u00adra\u00adted sales of just under 18.1 billion euros. At more than three billion euros, rese\u00adarch &amp; deve\u00adlo\u00adp\u00adment expen\u00addit\u00adures corre\u00adspond to 17.0 percent of&nbsp;sales.<\/p>\n<p>The law firm <strong>Maybach<\/strong> <strong>G\u00f6rg Lenn\u00adeis Ger\u00e9d<\/strong> Rechts\u00adan\u00adw\u00e4lte GmbH advi\u00adsed on Austrian law.<\/p>\n<p> <strong>Dr. Jan Wilhelm Bolt<\/strong> from Boeh\u00adrin\u00adger Ingel\u00adheim\u2019s legal depart\u00adment was in charge of the transaction.<\/p>\n<p><strong>Advi\u00adsor Boeh\u00adrin\u00adger Ingel\u00adheim: Gleiss Lutz<\/strong><br>\nDr. Martin Viciano Gofferje (Part\u00adner, Lead, Corporate\/M&amp;A, Berlin), Dr. Alex\u00adan\u00adder Schwarz (Part\u00adner, Corporate\/M&amp;A, D\u00fcssel\u00addorf) and Dr. Herwig Lux (Coun\u00adsel, IP, Stutt\u00adgart) advi\u00adsed Boeh\u00adrin\u00adger Ingel\u00adheim on this transaction.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ingel\u00adheim am Rhein, Germany \u2014 German phar\u00admaceu\u00adti\u00adcal group Boeh\u00adrin\u00adger Ingel\u00adheim has acqui\u00adred all shares in Austria-based Vira\u00adThe\u00adra\u00adpeu\u00adtics GmbH, a biophar\u00admaceu\u00adti\u00adcal company rese\u00adar\u00adching inno\u00adva\u00adtive virus-based immu\u00adno\u00adthe\u00adra\u00adpeu\u00adtics for the treat\u00adment of cancer. Through this biotech acqui\u00adsi\u00adtion with a tran\u00adsac\u00adtion volume of 210 million euros, Boeh\u00adrin\u00adger Ingel\u00adheim is further expan\u00adding its commit\u00adment in this area. Boeh\u00adrin\u00adger Ingel\u00adheim&nbsp;was&nbsp;[\u2026]<\/p>\n","protected":false},"author":2,"featured_media":42349,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[886,1364,1366],"tags":[],"class_list":["post-42342","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general-en","category-featured-en","category-news-en","news-category-deals-news-en"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Gleiss Lutz advises Boehringer Ingelheim on acquisition of Viratherapeutics - FYB Financial Yearbook<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fyb.de\/en\/gleiss-lutz-advises-boehringer-ingelheim-on-acquisition-of-viratherapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gleiss Lutz advises Boehringer Ingelheim on acquisition of Viratherapeutics - FYB Financial Yearbook\" \/>\n<meta property=\"og:description\" content=\"Ingel\u00adheim am Rhein, Germany \u2014 German phar\u00admaceu\u00adti\u00adcal group Boeh\u00adrin\u00adger Ingel\u00adheim has acqui\u00adred all shares in Austria-based Vira\u00adThe\u00adra\u00adpeu\u00adtics GmbH, a biophar\u00admaceu\u00adti\u00adcal company rese\u00adar\u00adching inno\u00adva\u00adtive virus-based immu\u00adno\u00adthe\u00adra\u00adpeu\u00adtics for the treat\u00adment of cancer. Through this biotech acqui\u00adsi\u00adtion with a tran\u00adsac\u00adtion volume of 210 million euros, Boeh\u00adrin\u00adger Ingel\u00adheim is further expan\u00adding its commit\u00adment in this area. Boeh\u00adrin\u00adger Ingel\u00adheim was [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fyb.de\/en\/gleiss-lutz-advises-boehringer-ingelheim-on-acquisition-of-viratherapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"FYB Financial Yearbook\" \/>\n<meta property=\"article:published_time\" content=\"2018-09-14T16:18:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/09\/a-bocc88hringer-e1536941884985.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1082\" \/>\n\t<meta property=\"og:image:height\" content=\"690\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Tatjana Anderer\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tatjana Anderer\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.fyb.de\/en\/gleiss-lutz-advises-boehringer-ingelheim-on-acquisition-of-viratherapeutics\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/gleiss-lutz-advises-boehringer-ingelheim-on-acquisition-of-viratherapeutics\/\"},\"author\":{\"name\":\"Tatjana Anderer\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\"},\"headline\":\"Gleiss Lutz advises Boehringer Ingelheim on acquisition of Viratherapeutics\",\"datePublished\":\"2018-09-14T16:18:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/gleiss-lutz-advises-boehringer-ingelheim-on-acquisition-of-viratherapeutics\/\"},\"wordCount\":275,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/gleiss-lutz-advises-boehringer-ingelheim-on-acquisition-of-viratherapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/09\/a-bocc88hringer-e1536941884985.jpg\",\"articleSection\":[\"General\",\"Featured\",\"News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.fyb.de\/en\/gleiss-lutz-advises-boehringer-ingelheim-on-acquisition-of-viratherapeutics\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.fyb.de\/en\/gleiss-lutz-advises-boehringer-ingelheim-on-acquisition-of-viratherapeutics\/\",\"url\":\"https:\/\/www.fyb.de\/en\/gleiss-lutz-advises-boehringer-ingelheim-on-acquisition-of-viratherapeutics\/\",\"name\":\"Gleiss Lutz advises Boehringer Ingelheim on acquisition of Viratherapeutics - FYB Financial Yearbook\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/gleiss-lutz-advises-boehringer-ingelheim-on-acquisition-of-viratherapeutics\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/gleiss-lutz-advises-boehringer-ingelheim-on-acquisition-of-viratherapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/09\/a-bocc88hringer-e1536941884985.jpg\",\"datePublished\":\"2018-09-14T16:18:19+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.fyb.de\/en\/gleiss-lutz-advises-boehringer-ingelheim-on-acquisition-of-viratherapeutics\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.fyb.de\/en\/gleiss-lutz-advises-boehringer-ingelheim-on-acquisition-of-viratherapeutics\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/gleiss-lutz-advises-boehringer-ingelheim-on-acquisition-of-viratherapeutics\/#primaryimage\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/09\/a-bocc88hringer-e1536941884985.jpg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/09\/a-bocc88hringer-e1536941884985.jpg\",\"width\":1082,\"height\":690},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.fyb.de\/en\/gleiss-lutz-advises-boehringer-ingelheim-on-acquisition-of-viratherapeutics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.fyb.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gleiss Lutz advises Boehringer Ingelheim on acquisition of Viratherapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.fyb.de\/en\/#website\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"name\":\"FYB Financial Yearbook\",\"description\":\"For Your Business\",\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.fyb.de\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\",\"name\":\"FYB Financial Yearbook\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"caption\":\"FYB Financial Yearbook\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\",\"name\":\"Tatjana Anderer\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"caption\":\"Tatjana Anderer\"},\"description\":\"Gr\u00fcnderin des FYB-Verlag\",\"sameAs\":[\"http:\/\/neu.fyb.de\"],\"url\":\"https:\/\/www.fyb.de\/en\/author\/tanderer\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Gleiss Lutz advises Boehringer Ingelheim on acquisition of Viratherapeutics - FYB Financial Yearbook","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fyb.de\/en\/gleiss-lutz-advises-boehringer-ingelheim-on-acquisition-of-viratherapeutics\/","og_locale":"en_US","og_type":"article","og_title":"Gleiss Lutz advises Boehringer Ingelheim on acquisition of Viratherapeutics - FYB Financial Yearbook","og_description":"Ingel\u00adheim am Rhein, Germany \u2014 German phar\u00admaceu\u00adti\u00adcal group Boeh\u00adrin\u00adger Ingel\u00adheim has acqui\u00adred all shares in Austria-based Vira\u00adThe\u00adra\u00adpeu\u00adtics GmbH, a biophar\u00admaceu\u00adti\u00adcal company rese\u00adar\u00adching inno\u00adva\u00adtive virus-based immu\u00adno\u00adthe\u00adra\u00adpeu\u00adtics for the treat\u00adment of cancer. Through this biotech acqui\u00adsi\u00adtion with a tran\u00adsac\u00adtion volume of 210 million euros, Boeh\u00adrin\u00adger Ingel\u00adheim is further expan\u00adding its commit\u00adment in this area. Boeh\u00adrin\u00adger Ingel\u00adheim was [&hellip;]","og_url":"https:\/\/www.fyb.de\/en\/gleiss-lutz-advises-boehringer-ingelheim-on-acquisition-of-viratherapeutics\/","og_site_name":"FYB Financial Yearbook","article_published_time":"2018-09-14T16:18:19+00:00","og_image":[{"width":1082,"height":690,"url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/09\/a-bocc88hringer-e1536941884985.jpg","type":"image\/jpeg"}],"author":"Tatjana Anderer","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Tatjana Anderer","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.fyb.de\/en\/gleiss-lutz-advises-boehringer-ingelheim-on-acquisition-of-viratherapeutics\/#article","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/gleiss-lutz-advises-boehringer-ingelheim-on-acquisition-of-viratherapeutics\/"},"author":{"name":"Tatjana Anderer","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce"},"headline":"Gleiss Lutz advises Boehringer Ingelheim on acquisition of Viratherapeutics","datePublished":"2018-09-14T16:18:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fyb.de\/en\/gleiss-lutz-advises-boehringer-ingelheim-on-acquisition-of-viratherapeutics\/"},"wordCount":275,"commentCount":0,"publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"image":{"@id":"https:\/\/www.fyb.de\/en\/gleiss-lutz-advises-boehringer-ingelheim-on-acquisition-of-viratherapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/09\/a-bocc88hringer-e1536941884985.jpg","articleSection":["General","Featured","News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.fyb.de\/en\/gleiss-lutz-advises-boehringer-ingelheim-on-acquisition-of-viratherapeutics\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.fyb.de\/en\/gleiss-lutz-advises-boehringer-ingelheim-on-acquisition-of-viratherapeutics\/","url":"https:\/\/www.fyb.de\/en\/gleiss-lutz-advises-boehringer-ingelheim-on-acquisition-of-viratherapeutics\/","name":"Gleiss Lutz advises Boehringer Ingelheim on acquisition of Viratherapeutics - FYB Financial Yearbook","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.fyb.de\/en\/gleiss-lutz-advises-boehringer-ingelheim-on-acquisition-of-viratherapeutics\/#primaryimage"},"image":{"@id":"https:\/\/www.fyb.de\/en\/gleiss-lutz-advises-boehringer-ingelheim-on-acquisition-of-viratherapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/09\/a-bocc88hringer-e1536941884985.jpg","datePublished":"2018-09-14T16:18:19+00:00","breadcrumb":{"@id":"https:\/\/www.fyb.de\/en\/gleiss-lutz-advises-boehringer-ingelheim-on-acquisition-of-viratherapeutics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fyb.de\/en\/gleiss-lutz-advises-boehringer-ingelheim-on-acquisition-of-viratherapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/gleiss-lutz-advises-boehringer-ingelheim-on-acquisition-of-viratherapeutics\/#primaryimage","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/09\/a-bocc88hringer-e1536941884985.jpg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/09\/a-bocc88hringer-e1536941884985.jpg","width":1082,"height":690},{"@type":"BreadcrumbList","@id":"https:\/\/www.fyb.de\/en\/gleiss-lutz-advises-boehringer-ingelheim-on-acquisition-of-viratherapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fyb.de\/en\/"},{"@type":"ListItem","position":2,"name":"Gleiss Lutz advises Boehringer Ingelheim on acquisition of Viratherapeutics"}]},{"@type":"WebSite","@id":"https:\/\/www.fyb.de\/en\/#website","url":"https:\/\/www.fyb.de\/en\/","name":"FYB Financial Yearbook","description":"For Your Business","publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fyb.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.fyb.de\/en\/#organization","name":"FYB Financial Yearbook","url":"https:\/\/www.fyb.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","caption":"FYB Financial Yearbook"},"image":{"@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce","name":"Tatjana Anderer","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","caption":"Tatjana Anderer"},"description":"Gr\u00fcnderin des FYB-Verlag","sameAs":["http:\/\/neu.fyb.de"],"url":"https:\/\/www.fyb.de\/en\/author\/tanderer\/"}]}},"_links":{"self":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/42342","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/comments?post=42342"}],"version-history":[{"count":0,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/42342\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media\/42349"}],"wp:attachment":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media?parent=42342"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/categories?post=42342"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/tags?post=42342"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}